Back to search

Article

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma

2020-12-23

Abstract excerpt

<h4>Background: </h4> Ovarian cancer patients with tumors positive for homologous recombination deficiency (HRD) would benefit from PAPR inhibitor (PAPRi)therapy. However, patients with HRD-positive tumors account for less than 50% of the whole cohort. So new biomarkers still need to be developed. The aim of this study was to identify biomarkers complementary to HRD for improving the clinical outcome of ovarian se...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f5c899d0-9295-5ac9-8b38-7f65486facca
DOI
10.21203/rs.3.rs-131950/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinomaDOI 10.21203/rs.3.rs-131950/v1
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.Semantic proximity
Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity
The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity
Molecular Pathogenesis Early Detection Strategies and Precision Therapeutic Advances in Ovarian CancerSemantic proximity
Identification of three subtypes of ovarian cancer and construction of prognostic models based on immune-related genes.Semantic proximity
Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the MoonSemantic proximity
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity
Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.Semantic proximity
Select a neighboring publication to make it the new centre.